000597.SZ
东北制药
SZSE · Healthcare · C 制造业 · CN
CNY 4.88
−2.59%Year over year
Reported trailing growth
- Revenue
- -5.0%
- EBITDA
- —
- EBIT
- -50.7%
- EPS
- -36.7%
- Free cash flow
- +114.3%
- Operating cash flow
- +82.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -7.0%
- EBITDA
- -12.0%
- EBIT
- -23.3%
- Net income
- -9.4%
- EPS
- -10.4%
- Free cash flow
- +5.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026